GlySure Appoints Heidi Hausner as U.S. Director of Clinical Affairs
ABINGDON, England, August 1, 2012 /PRNewswire/ --
GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems, today announced the appointment of Heidi Hausner, RN as its U.S. Director of Clinical Affairs. In this newly established position, Hausner will lead U.S. clinical regulatory trials for GlySure's CGM technology and support the company's clinical trials in Europe.
Hausner has more than 25 years of experience in both the manufacturing sector directing all aspects of medical device clinical trials, as well as sales field training and project management and in the clinical setting as a critical care operating room (OR) nurse.
Hausner most recently served as Senior Clinical Research Manager for Synthes, a market leader in trauma, cranio/maxillofacial and spine industries (now part of Johnson & Johnson), where she led the teams responsible for clinical investigations in both pre- and post-market environments.
"Hausner's strong background in clinical care and medical device trial management will be an invaluable asset as we embark on our U.S. and European trials this fall," said GlySure CEO Chris Jones. "Her experience both at the patient bedside and behind the scenes in product development and sales training will help drive the development of technology that meets the clinical demand for CGM while improving the efficiency and reducing the cost of care."
Hausner holds a Master of Science degree in Quality Assurance and Regulatory Affairs and a certificate in Clinical Trial Management from Temple University School of Pharmacy, a Bachelor of Health Science in Management degree from Gwynedd Mercy College and a diploma in Nursing from St. Luke's Hospital School of Nursing.
About GlySure:
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com
Company Contact:Chris Jones, CEO, GlySure, Tel: +44(0)1235-462-870, cjones@glysure.com
Media Contact:Bruce Dodworth, Sea Glass PR, Tel: +44(0)1780-769069, bruce@seaglasspr.com
SOURCE GlySure Limited